Human Metabolome Technologies (6090) · FactRestatedLatest General Meetings of Shareholders (2026-08-25): "Cited as achieved"
Growth Opportunities in the Bioeconomy Market and Biomanufacturing
First written in FY2024. 1 of 3 entries say "Restated". Latest entry: 2026-08-25.
3entries
3years
1from disclosures
How it moved
Same theme, other companies
Expansion of the Biomanufacturing and Bioeconomy MarketsA theme 2 companies write about · 0 as a headwind · 2 as a tailwind
1 other company's latest entry also says "Cited as achieved".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- 2026-08-25Cited as achievedGeneral Meetings of Shareholders
「Research and development related to bio-manufacturing, one of the government’s 17 strategic fields, has also become more active.」
The company cited the increasing activity in bio-manufacturing-related research and development as part of its business environment and opportunity context. - FY2025-H1RestatedAnnual report
「Research and development in the bioindustry is also expected to increase as a result of policies promoting the bioeconomy.」
The company continues to identify the expected increase in R&D in the bioindustry, driven by bioeconomy promotion policies, as a business opportunity. - FY2024First statedAnnual report
「Some estimates indicate that the bioeconomy market will grow from ¥200 trillion in 2030 to ¥400 trillion in 2040, while the bioeconomy strategy targets a market size of ¥100 trillion in 2030.」
Against the backdrop of the government’s Bioeconomy Strategy 2024, the company identified for the first time, as an independent opportunity in its business environment, the expansion of the biomanufacturing market, which contributes to reducing environmental impact, achieving a resource-circulating economy and ensuring a stable food supply.